Alembic Pharmaceuticals (APLLTD) Q4 11/12 earnings summary

Executive summary

• FY12 standalone revenue from operations was ₹1,375.28 crore and net profit ₹120.54 crore; consolidated revenue was ₹1,466.39 crore and net profit ₹130.13 crore.

• Domestic branded formulations grew 13%; regulatory-market export formulations grew 39%, while API exports grew 55%.

Financial highlights

• Standalone profit before interest, depreciation and tax was ₹210.01 crore versus ₹155.81 crore; consolidated was ₹220.85 crore versus ₹160.32 crore.

• Standalone total revenue was ₹1,375.73 crore versus ₹1,165.01 crore; consolidated total revenue was ₹1,466.83 crore versus ₹1,202.13 crore.

• Standalone finance costs were ₹26.21 crore versus ₹23.89 crore; net profit rose to ₹120.54 crore from ₹81.51 crore.

• Consolidated net profit was ₹130.13 crore versus ₹85.39 crore; finance costs were ₹26.21 crore versus ₹23.89 crore.

Outlook and guidance

• Industry outlook was viewed as favorable, supported by domestic formulation growth and expected U.S./Europe generics demand from patent expiries.

• Growth opportunities included cost-efficient sourcing, development services and progression to commercial-scale production; successful global regulatory inspections supported readiness.

• Timely, accelerated ANDA/DMF filings, low-cost products and strong intellectual property were identified as priorities for international generics growth.